FENC — FENNEC PHARMACEUTICALS INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1211583 ·
Last close
$9.89
Market Cap
$343.55M
52W High
$10.45
52W Low
$5.65
ADV30
249,036
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 15,108,000 | 14,538,000 | -119,000 | 201,000 | 71,822,000 | 40,179,000 | 34,147,000 |
| Dec 2025 | 13,777,000 | 12,013,000 | -2,580,000 | -4,787,000 | 70,551,000 | 36,788,000 | 35,079,000 |
| Sep 2025 | 12,462,000 | 11,802,000 | -201,000 | -638,000 | 49,261,000 | 21,947,000 | 53,753,000 |
| Jun 2025 | 9,652,000 | 8,685,000 | -2,732,000 | -3,152,000 | 44,876,000 | 18,705,000 | 52,339,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,473,000
Investing CF
—
Financing CF
$22,627,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.34
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-229,422,000
Inventory
$1,565,000
Receivables
$23,221,000
ST Investments
—
EBIT TTM
$-7,556,000
Pretax Income TTM
$-9,636,000
Interest Exp TTM
$2,080,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$50,999,000
EBITDA
$-5,490,333
Free Cash Flow
$-2,370,875
Enterprise Value
$303,370,240
Total Cash
$40,179,000
Total Debt
$0
Shares Out
34,737,030
Trailing EPS
$-0.29
Book Value
$1.09
ROE
-52.7%
ROA
-5.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 44,642,000 | -6,346,000 | -9,741,000 | 70,551,000 | — | — | -12,473,000 |
| Dec 2024 | 47,538,000 | 2,479,000 | -436,000 | 44,946,000 | — | — | 26,980,000 |
| Dec 2023 | 21,252,000 | -13,058,000 | -16,045,000 | 26,864,000 | — | — | -17,143,000 |
| Dec 2022 | 1,535,000 | -22,738,000 | -23,714,000 | 26,939,000 | — | — | -18,058,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PALI | PALISADE BIO, INC. | $345.42M | $1.99 | — |
| NMRA | Neumora Therapeutics, Inc. | $340.92M | $1.84 | — |
| PROK | PROKIDNEY CORP. | $346.79M | $1.69 | — |
| RGNX | REGENXBIO Inc. | $326.21M | $6.31 | — |
| IVVD | Invivyd, Inc. | $324.07M | $1.10 | — |
News headlines (Yahoo Finance, 1h cache)
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter
2026-05-23 14:05 · Yahoo
Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting
2026-05-22 11:21 · Yahoo
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
2026-05-21 22:01 · Yahoo
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-18 20:30 · Yahoo
Fennec Pharmaceuticals Inc (FENC) Q1 2026 Earnings Call Highlights: Record Sales Surge and ...
2026-05-14 23:03 · Yahoo
Fennec Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
2026-05-14 21:11 · Yahoo
Do Options Traders Know Something About Adherex Technologies Stock We Don't?
2026-05-14 15:32 · Yahoo
Adherex Technologies Q1 Earnings Call Highlights
2026-05-14 15:06 · Yahoo
Fennec Pharmaceuticals Shares Rise After Earnings and Revenue Beat Forecasts (FENC)
2026-05-14 12:47 · Yahoo
Fennec Pharmaceuticals up 12.6% in U.S. Pre-Market on Q1 Earnings as Pedmark Sales Jump 73%
2026-05-14 11:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.